MET and cancer: Notably, it has been demonstrated that p53-mediated miR-34a transactivation negatively regulates MET expression, identifying a p53/miR-34a/c-Met regulatory network and suggesting the inhibition of MET as an effective antimetastatic approach to treat cancers bearing mutated p53 [21].